4:07 PM ET
8-K
Business Update
Caribou Biosciences Business Update
Caribou Biosciences is exploring strategic alternatives and implementing a restructuring plan that includes discontinuing its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011. The company is conducting a substantial workforce reduction and expects to incur restructuring charges between $15 million and $19 million, primarily for severance and clinical trial wind-down costs.